Evidence map›Paper›PMID 31586137›Full record

ArticleScientific reports2019

Digitizable therapeutics for decentralized mitigation of global pandemics.

Adar Hacohen, Reuven Cohen, Sol Efroni, Baruch Barzel, Ido Bachelet

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adar HacohenAugmanity, Rehovot, Israel.
Reuven CohenDepartment of Mathematics, Bar-Ilan University, Ramat-Gan, Israel.ORCID http://orcid.org/0000-0001-8788-2189
Sol EfroniFaculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.ORCID http://orcid.org/0000-0001-7927-6349
Baruch BarzelDepartment of Mathematics, Bar-Ilan University, Ramat-Gan, Israel. baruchbarzel@gmail.com.ORCID http://orcid.org/0000-0001-8862-4384
Ido BacheletAugmanity, Rehovot, Israel.ORCID http://orcid.org/0000-0002-1089-1172

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When confronted with a globally spreading epidemic, we seek efficient strategies for drug dissemination, creating a competition between supply and demand at a global scale. Propagating along similar networks, e.g., air-transportation, the spreading dynamics of the supply vs. the demand are, however, fundamentally different, with the pathogens driven by contagion dynamics, and the drugs by commodity flow. We show that these different dynamics lead to intrinsically distinct spreading patterns: while viruses spread homogeneously across all destinations, creating a concurrent global demand, commodity flow unavoidably leads to a highly uneven spread, in which selected nodes are rapidly supplied, while the majority remains deprived. Consequently, even under ideal conditions of extreme production and shipping capacities, due to the inherent heterogeneity of network-based commodity flow, efficient mitigation becomes practically unattainable, as homogeneous demand is met by highly heterogeneous supply. Therefore, we propose here a decentralized mitigation strategy, based on local production and dissemination of therapeutics, that, in effect, bypasses the existing distribution networks. Such decentralization is enabled thanks to the recent development of digitizable therapeutics, based on, e.g., short DNA sequences or printable chemical compounds, that can be distributed as digital sequence files and synthesized on location via DNA/3D printing technology. We test our decentralized mitigation under extremely challenging conditions, such as suppressed local production rates or low therapeutic efficacy, and find that thanks to its homogeneous nature, it consistently outperforms the centralized alternative, saving many more lives with significantly less resources.

Indexed as

Global HealthBioprintingDisease Transmission, InfectiousDNADrug CompoundingHumansPandemicsPharmaceutical PreparationsPrinting, Three-DimensionalRisk Evaluation and MitigationDNAPharmaceutical Preparations

Identifiers

PMID31586137
PMCPMC6778202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.